Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories reports developments across a global healthcare portfolio that includes diagnostics, medical devices, nutritionals and branded generic medicines. Recurring updates cover cardiovascular technologies such as Ultreon coronary imaging, pulsed field ablation and cardiac pacing systems; diabetes and other medical devices; nutritional products; and diagnostic testing.
Abbott news also includes financial results, guidance, product clearances, clinical data presentations, commercial integrations and portfolio changes. Following the completed Exact Sciences acquisition, oncology diagnostics are a recurring theme, including Cologuard, Oncotype DX, Oncodetect, Riskguard and Cancerguard tests for cancer screening, recurrence risk and treatment support.
Abbott (NYSE: ABT) reported second-quarter 2026 sales of $12.6 billion, up 13.0% on a reported basis and 4.8% on a comparable basis. GAAP diluted EPS was $0.53 and adjusted diluted EPS was $1.31, excluding specified items. According to Abbott, the company reaffirmed full-year 2026 comparable sales growth guidance of 6.5%–7.5% and raised full-year adjusted EPS guidance to $5.45–$5.60 from $5.38–$5.58, and guided third-quarter adjusted EPS to $1.38–$1.46.
Diagnostics sales rose 42.3% reported (2.9% comparable), Medical Devices grew 9.0% reported (8.4% comparable), Established Pharmaceuticals grew 8.4% reported (8.7% comparable), while Nutrition declined 3.1% reported (3.6% comparable). Abbott returned $2.1 billion to shareholders via dividends and buybacks and declared its 410th consecutive quarterly dividend. The quarter also included completion of enrollment in the TECTONIC pivotal trial, CE Mark for Libre Duo, FDA submission for Amulet 360, and new data supporting pulsed field ablation and conduction system pacing portfolios.
Abbott (NYSE:ABT) plans to release its second-quarter 2026 earnings on Thursday, July 16, 2026, before the market opens.
The earnings release will be followed by a live webcast conference call at 8 a.m. CT (9 a.m. ET), available via Abbott's investor relations website.
ALZpath announced a global licensing agreement with Abbott (NYSE: ABT) to use ALZpath’s proprietary pTau217 antibody in developing an in vitro diagnostic blood test for Alzheimer’s disease on Abbott’s Alinity ci-series systems.
The antibody is supported by 200+ publications across 18 countries and aims to offer a scalable blood-based alternative to PET imaging and cerebrospinal fluid analysis for earlier Alzheimer’s detection and potential disease monitoring.
Similac (NYSE:ABT) released survey findings on how social media affects young parents and launched its “Love Without Measure” initiative. A national online survey of 1,002 U.S. adults aged 22-32 found 93% expect parenthood to be fulfilling, yet nearly 80% feel pressure to be “perfect” on social media.
The initiative encourages parents to share unfiltered stories using #LoveWithoutMeasure, partners with motherhood experts and influencers, and promotes realistic, judgment-free parenting content across Instagram, Facebook, TikTok and Similac.com.
Abbott (NYSE: ABT) declared a quarterly common dividend of $0.63 per share, its 410th consecutive quarterly dividend since 1924. The cash dividend is payable August 17, 2026 to shareholders of record on July 15, 2026.
Abbott has raised its dividend for 54 straight years and is part of the S&P 500 Dividend Aristocrats Index.
Abbott (NYSE:ABT) reported new research from its Healthy Food Rx “Food is Medicine” program, paired with community health worker coaching, in 284 adults with type 2 diabetes over six months.
Participants showed higher fruit, vegetable and water intake, more physical activity, better self-management, improved self-reported health and reduced food insecurity.
Abbott (NYSE:ABT) released new data showing diabetic ketoacidosis (DKA) is rising across age groups and can be difficult to recognize early, especially at hospital admission. Studies cited report about a 24% rise in DKA hospitalizations for Type 1 diabetes between 2017-2024 and nearly 60% of pediatric diabetes hospitalizations driven by DKA.
Abbott highlights gaps in ketone awareness and testing and notes that most continuous glucose monitors do not measure ketones. The company has developed dual glucose-ketone sensors, Libre Duo and Libre Duo 10 Day, which obtained CE Mark in May 2026 and are pending FDA clearance.
Abbott (NYSE: ABT) received CE Mark for Libre Duo and Libre Duo 10 Day, the world's first dual continuous glucose‑ketone sensing systems for people with diabetes. The sensors measure both biomarkers every minute, support daily glucose management, and may help detect rising ketones linked to diabetic ketoacidosis (DKA).
Libre Duo offers up to 15 days of wear for adults; Libre Duo 10 Day provides up to 10 days for users aged 2 and older. Both integrate with Abbott's Libre digital ecosystem and are designed for compatibility with automated insulin delivery systems. Libre Duo is not yet cleared or available in the United States; launches in select European countries are planned later in 2026.
Abbott (NYSE:ABT) announced that updated American Cancer Society colorectal cancer screening guidelines reaffirm Cologuard and Cologuard Plus as preferred noninvasive options for average‑risk adults 45+ on a three‑year interval.
Abbott highlights strong test performance, real‑world adherence, and plans to commercialize a complementary blood‑based test pending FDA approval.
Abbott (NYSE:ABT) will showcase 11 cancer diagnostics abstracts at the ASCO 2026 Annual Meeting in Chicago, May 29–June 2, 2026. Presentations span multi-cancer early detection, molecular residual disease, breast recurrence risk, colorectal screening and pipeline innovation.
Highlights include new MRD data from the PARTNER trial in early triple-negative breast cancer, early real-world data on the Cancerguard multi-cancer early detection blood test, AI-driven risk stratification using the Oncotype DX Breast Recurrence Score, a vaginal-swab-based endometrial cancer test, and updated analyses for the Cologuard colorectal cancer screening test.